It’s tempting to make a “shot themselves in the foot” pun with respect to the problems Wright Medical (WMGI)
got itself into over the last couple of years, but this
extremities-focused orthopedics company does seem to be getting its
house back in order. Not only should the approval and launch of the
injectable form of Augment spur meaningful adoption growth, but the
company’s shoulder business continues to perform very well, and it looks
as though management has the traditional foot and ankle business back
on track.
Wright Medical shares have given investors
plenty of trading opportunities over the last few years, as the company
has struggled to establish a consistent growth path after the Tornier
deal. I believe the company is getting there, and I’ve been impressed
with the company’s internal R&D engine. The shares do still seem to
offer some upside, and over the long-term a buyout is still a
possibility, but investors should appreciate that there is a history of
inconsistent execution here.
Read more here:
Wright Medical Getting Its House Back In Order
No comments:
Post a Comment